View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 2, 2019

Trial shows promise for treating PTSD with FAAH inhibitors

A clinical trial by Linköping University in Sweden has shown that a new medication, designed to block the fatty acid amide hydrolase (FAAH) enzyme, could help treat post-traumatic stress disorder (PTSD).

Prolonged exposure therapy is a typical treatment for PTSD. Patients are exposed repeatedly to their traumatic memory in a bid to determine that the memories no longer indicate imminent danger.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

The effects of prolonged exposure therapy are limited and associated with the return of fears over time. To address this, researchers have evaluated a medicine that could enhance the treatment.

Supplied by Pfizer, the drug targets the body’s endocannabinoid system, which regulates fear and stress-related behaviours.

It increases the levels of anandamide in the brain regions that control fear and anxiety. The inhibition of FAAH, which breaks down anandamide, causes this increase.

The randomised, placebo-controlled and double-blind trial by Linköping researchers compared the drug to placebo in a total of 45 healthy volunteers.

Following a treatment period of ten days, participants received various psychological and physiological tests.

One test coupled a highly unpleasant sound with a visual cue.

Once participants learned to respond with fear to the visual cue, they were repeatedly re-exposed to it without the unpleasant sound, to facilitate unlearning of the fear memory.

When compared, volunteers treated with the FAAH inhibitor were observed to remember the fear extinction memory more successfully.

Linköping University senior post-doctoral fellow and study lead investigator Leah Mayo said: “We have used a medication that blocks the way the body breaks down its own cannabis-like substances, or ‘endocannabinoids’.

“Our study shows that this class of medications, called FAAH inhibitors, may offer a new way to treat PTSD and perhaps also other stress-related psychiatric conditions. The next important step will be to see if this type of medication works in patients, particularly those with PTSD.”

Partial funding of the study came from the Swedish Research Council and the Canadian Institutes of Health Research.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena